Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Abbott Xience V Coronary Stent Demonstrates Low Rate Of Blood Clots

Abbott has presented two clinical trials data at the EuroPCR 2010 conference supporting Xience V Everolimus Eluting Coronary Stent System. In the Xience V US study of more than 5,000 real-world, complex patients, Xience V demonstrated a low rate of blood clots (stent thrombosis) at one year (0.84% per Academic Research Consortium [ARC] definition of definite/probable stent thrombosis).

In a subset of approximately 1,800 less complex patients (referred to as ‘standard risk’), Xience V demonstrated a one-year stent thrombosis rate of 0.34% per ARC definition of definite/probable stent thrombosis.

Abbott said that the Xience V USA study also showed that stent thrombosis rates remained low even when dual anti-platelet therapy (DAPT) was temporarily or permanently discontinued. In the overall Xience V USA population, patients who interrupted DAPT usage after six months showed a subsequent late stent thrombosis rate of zero percent.

In the subset of standard risk patients, those who interrupted DAPT usage after 30 days also showed a subsequent late stent thrombosis rate of zero percent. DAPT compliance in the Xience V USA study was 79.4% at one year.

James Hermiller, director of Cardiovascular Interventions, St Vincent Hospital in Indianapolis, and principal investigator of the Xience V USA trial, said: “The low stent thrombosis rate demonstrated by Xience V is impressive given the complexity of the patient population included in the Xience V USA trial, and confirms that the stent thrombosis results seen with Xience V in earlier randomized clinical trials are consistent in real-world clinical practice.”